LP
ASBPW

LMR Partners’s Aspire Biopharma Warrant ASBPW Stock Holding History

LMR Partners’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-125,000
Closed -$5.29K – 1688
2024
Q3 		$5.29K Buy
+125,000
New +$5.95K ﹤0.01% 1178

Other funds holding ASBPW

SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

LMR Partners's ASBPW Position: Q2 2026 in Review

LMR Partners held its Aspire Biopharma Warrant (ASBPW) position steady in Q2 2026 at 125,000 shares worth $2.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1473.

LMR Partners first reported a position in ASBPW in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.31M in Q1 2023. 27 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

  • LMR Partners held 125,000 shares of Aspire Biopharma Warrant worth $2.5K as of Q2 2026.
  • LMR Partners left its Aspire Biopharma Warrant share count unchanged in Q2 2026.
  • Aspire Biopharma Warrant made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1473 holding.
  • LMR Partners first reported a position in Aspire Biopharma Warrant in Q4 2022 and has held it in 14 quarters since.
  • LMR Partners's Aspire Biopharma Warrant position peaked at $1.31M in Q1 2023.
  • 27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.